Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
DSIP / Emideltide
A neuropeptide named for a sleep effect first described in the 1970s that decades of follow-up have never clearly replicated in humans.
Semax
A synthetic heptapeptide derived from an ACTH fragment, registered as nasal drops in Russia and heavily marketed elsewhere as a nootropic.
How far human research has progressed
DSIP / Emideltide
Historical small studies with inconsistent resultsSemax
Registered in one national market; limited Western-quality controlled evidenceClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
DSIP / Emideltide
Not separately assessed; see the full profile.Semax
Not separately assessed; see the full profile.Human research context
DSIP / Emideltide
Historical small studies with inconsistent resultsSemax
Registered in one national market; limited Western-quality controlled evidenceHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
DSIP / Emideltide
Semax
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
DSIP / Emideltide
Semax
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
DSIP / Emideltide
Semax
Regulatory status (legal position, not proof it works)
DSIP / Emideltide
Check jurisdiction-specific details in the profile.
Not an approved medicine in any major region. FDA has identified it as a bulk substance presenting significant safety risks for compounding; that listing status changed during 2026, and DSIP (emideltide) was covered by FDA's Pharmacy Compounding Advisory Committee meeting on 23-24 July 2026 across insomnia, opioid-withdrawal and narcolepsy-related nominations.
Semax
Check jurisdiction-specific details in the profile.
Not approved by the FDA or other major Western regulators. FDA material notes Semax is registered in Russia as nasal drops, while intranasal and injectable products marketed in the US are not FDA-approved. FDA has identified it as a bulk substance presenting significant safety risks for compounding — a compounding safety classification, not an 'FDA ban' — and it was covered by FDA's Pharmacy Compounding Advisory Committee meeting on 23-24 July 2026.
Common claims
DSIP / Emideltide
- · Induces deep sleep
- · Helps insomnia, opioid withdrawal and narcolepsy
Semax
- · Improves memory, focus and mental performance
- · Speeds recovery after stroke
- · Helps anxiety and migraine
How settled our evidence rating is
DSIP / Emideltide
Semax
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
DSIP / Emideltide
No established human cancer signal; systematically unstudied.Semax
No established human cancer signal and no systematic data either way. The honest position is unstudied.What this adds up to, in plain English
DSIP / Emideltide
This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.Semax
The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.A comparison is not a recommendation